AstraZeneca’s reported USD 400bn bid for Bristol Myers Squibb may have come to nothing, but it highlights the enduring appeal of transformational pharma mergers. Such ambitious deals are likely to remain the preserve of companies with proven credibility.
By Sabrine Boudella, Director, Corporate Ratings
In AstraZeneca’s case, the capacity to even consider a deal with BMS stems partly from the transformation of the company’s performance since Pascal Soriot's arrival as chief executive of the UK-based firm in 2012, two years before AstraZeneca successfully fought off a takeover bid from Pfizer. AstraZeneca has also combined a bold but calculated approach to business risk with prudent financial policy.
Under Soriot, AstraZeneca has mixed selective acquisitions with hefty investment in its own research across multiple therapeutic areas while also expanding the use of licensing agreements and strategic collaborations – against the grain of industry specialisation.
While political and market scepticism about the motives for and outcomes of an AstraZeneca-BMS tie-up seems to have undermined the deal, the merger idea still has an important read across for other European players – particularly those needing to diversify away from concentrated blockbuster-drug revenues or replenish weak R&D pipelines for fear of a squeeze on cash flow in the medium term.
Transformational acquisitions are available only to companies whose investors trust management's capital allocation. AstraZeneca seems to have tested that to the limit, but the firm retains an enviable decade-plus record of sustained revenue growth, pipeline execution and integration of acquisitions such as Alexion Pharmaceuticals in 2020.
Investor confidence can make or break a deal
In 2012, AstraZeneca generated roughly USD 28bn of revenue and had a pipeline of 84 projects, including 71 clinical-stage assets, but only 11 projects in Phase III or under regulatory review.
Fast forward, and in 2025, revenue had reached almost USD59bn, EBITDA had increased to about USD 19.5bn and the pipeline had expanded to 197 projects, including 176 clinical-stage assets and around 20 new drugs in late-stage trials. This allowed management to set an ambitious revenue target of USD 80bn by 2030, a goal that now appears likely to have contemplated transformative M&A along with organic growth.
AstraZeneca has achieved this turnaround, not with a focus on a small number of therapeutic areas like many competitors, but by building leadership positions across oncology, rare disease, respiratory and immunology, and CVRM (Cardiovascular, Renal and Metabolism) and, more recently, pursuing opportunities in the fast-growing weight-loss segment.
Management’s approach has not always pleased investors, particularly the USD 39bn acquisition of Alexion. criticised at the time for diluting AstraZeneca’s focus on oncology.
AstraZeneca did not opt for the classic trade-off between internal and external growth. When acquiring Alexion, management also doubled down on internal R&D. That increased execution risk, but AstraZeneca has proved capable of creating new growth platforms while successfully managing existing ones.
Why this matters for BMS
BMS is dealing with issues that AstraZeneca has already faced, including expected patent cliffs, questions around future growth and increasing pressure to deliver returns from R&D investment, hence the opportunity that the UK-based firm has identified for external growth in the US.
In many respects, AstraZeneca today resembles the company BMS wishes to become: one that has successfully navigated concerns over patent expiries, rebuilt confidence in its pipeline and convinced investors that growth can extend beyond the next generation of blockbuster medicines.
AstraZeneca has credit strengths
Scope does not rate AstraZeneca, but we would note some fundamental credit strengths: one of the strongest pipelines in the industry and leverage of only around 1.2x at year-end 2025. This, in our view, provides headroom for potential debt issuance, even if a large acquisition like that of BMS would have had to have been predominantly equity financed.
Investors, while unimpressed with the BMS deal, have previously rewarded AstraZeneca's management for its risk appetite. The company’s market capitalisation is around EUR 212bn, compared with EUR 114bn for BMS, despite generating only moderately higher revenues of USD 58.7bn against USD 48.2bn.
Merger-related investor scepticism is understandable; AstraZeneca on its own has scale, strong cash generation and one of the industry's deepest pipelines, so many shareholders struggled to identify BMS-merger benefits that would outweigh execution risks and potential antitrust remedies.
These risks were not insurmountable, with the deal failing seemingly more over a lack of market and political conviction rather than economics. The merger had the potential to provide AstraZeneca with the scale and capacity to innovate in the long term in line with its higher-valued peers. However, the success of any transaction depends on its strategic merits and investor trust – which can never be taken for granted.